tradingkey.logo

Regeneron Expands Clinical-Stage Obesity Portfolio

ReutersJun 2, 2025 12:16 PM

- Regeneron Pharmaceuticals Inc REGN.O:

  • REGENERON EXPANDS CLINICAL-STAGE OBESITY PORTFOLIO WITH STRATEGIC IN-LICENSING OF NOVEL DUAL GLP-1/GIP RECEPTOR AGONIST

  • REGENERON PHARMACEUTICALS INC - TO PAY $80 MILLION UPFRONT TO HANSOH

  • REGENERON PHARMACEUTICALS INC: POTENTIAL ADDITIONAL PAYMENTS OF UP TO $1.93 BILLION UNDER DEAL

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI